Capricor Therapeutics to Host Webcast on FDA Updates for Duchenne Muscular Dystrophy Program

Capricor Therapeutics, a biotech firm pioneering treatments for rare diseases, will hold an investor webcast on Tuesday, September 24, 2024, at 8:30 a.m. ET. The webcast will focus on regulatory updates for Capricor’s Duchenne muscular dystrophy (DMD) program, following recent meetings with the U.S. Food and Drug Administration (FDA).

Investors and interested parties can join the webcast by dialing 1-800-717-1738 (toll-free) or 1-646-307-1865 (international), using conference ID: 62574. Alternatively, participants can access the webcast through Capricor’s website, with a replay available after the live broadcast.

Capricor Therapeutics is leading the way in developing transformative cell and exosome-based therapies. Its lead candidate, deramiocel (CAP-1002), a cardiac-derived cell therapy, is in Phase 3 clinical trials for DMD. The therapy shows promise with immunomodulatory and regenerative benefits, offering hope for treating dystrophinopathies and heart disease. Capricor is also advancing its exosome platform, StealthX™, aimed at vaccines and targeted therapeutics, opening new possibilities in treating a wide range of diseases.